Lichtstrasse 35
Basel 4056
Switzerland
41 61 324 1111
https://www.novartis.com
版塊: Healthcare
行業: Drug Manufacturers - General
全職員工: 76,057
名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
---|---|---|---|---|
Dr. Vasant Narasimhan M.D. | Chief Executive Officer | 7.99M | 無 | 1976 |
Mr. Harry Kirsch | Chief Financial Officer | 3.98M | 無 | 1965 |
Mr. Victor Bulto | President of US | 3.27M | 無 | 1978 |
Dr. Patrick Horber M.D. | President of International | 7.29M | 無 | 1970 |
Dr. Steffen Lang Ph.D. | President of Operations | 2.33M | 無 | 1967 |
Paul Penepent | Head of Group Financial Reporting and Accounting | 無 | 無 | 無 |
Dr. Klaus Moosmayer Ph.D. | Chief Ethics, Risk & Compliance Officer | 1.55M | 無 | 1968 |
Ms. Karen L. Hale | Chief Legal Officer | 2.34M | 無 | 1968 |
Dr. Robert Kowalski Pharm.D. | Chief People & Organization Officer | 2.1M | 無 | 1968 |
Etienne Jousseaume | Head of Market Access, Cell & Gene Europe | 無 | 無 | 無 |
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
截至 2024年5月1日 止,Novartis AG 的 ISS 管治質素評分為 1。 Pillar 分數正在審核中:1;董事會:2;股東權利:1;現金賠償:3。